Liquidia (NASDAQ:LQDA) Trading Down 6.6% Following Weak Earnings

Key Points

• Liquidia shares fell 6.6% after quarterly EPS of $0.74 narrowly missed the $0.76 consensus estimate, despite revenue of $171.68 million exceeding expectations and rising sharply year over year.
• YUTREPIA continued strong growth, generating approximately $170.4 million in second-quarter sales, with about 5,900 prescriptions and more than 5,000 patients treated since its June 2025 launch. Management is targeting over $1 billion in net revenue by 2027.
• Valuation and insider selling remain concerns: the stock trades at a very high earnings multiple, insiders have sold substantial shares, and higher research and development spending for the L606 Phase 3 program could pressure margins.

Liquidia Corporation (NASDAQ:LQDA - Get Free Report)'s share price dropped 6.6% during mid-day trading on Thursday after the company announced weaker than expected quarterly earnings. The company traded as low as $73.83 and last traded at $73.6150. Approximately 2,173,490 shares traded hands during mid-day trading, an increase of 22% from the average session volume of 1,784,219 shares. The stock had previously closed at $78.79.

The company reported $0.74 EPS for the quarter, missing analysts' consensus estimates of $0.76 by ($0.02). The company had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business's revenue for the quarter was up 1842.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.49) earnings per share.

Key Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA continues to scale rapidly. Second-quarter net product sales reached approximately $170.4 million, up 31% sequentially. Liquidia reported roughly 5,900 prescriptions and more than 5,000 patients treated since the product’s June 2025 launch. Liquidia Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Revenue, earnings quality and cash flow were strong. Total revenue rose to $171.7 million, ahead of the $168.5 million consensus estimate. Net income was $74.7 million, adjusted EBITDA was $96.3 million, and cash increased to $284.2 million at quarter-end. The results marked Liquidia’s fourth consecutive quarter of improving profitability. Liquidia Corporation Q2 Earnings and Revenues
• Positive Sentiment: Management reiterated an ambitious growth outlook. Liquidia is targeting more than $1 billion in 2027 net revenue as YUTREPIA gains market share. The company is also advancing 10 clinical studies involving YUTREPIA and L606, potentially expanding its inhaled-treprostinil opportunity. LQDA Q2 Earnings Call Highlights
• Positive Sentiment: Analysts raised their valuation targets. Needham increased its target to $110 and BTIG to $111, both retaining buy ratings. Bank of America raised its target to $92 but maintained a neutral rating, while Lifesci Capital reaffirmed market perform with a $90 target.
• Neutral Sentiment: The earnings picture was mixed. Diluted EPS of $0.74 was below the $0.76 consensus estimate cited by several outlets, although it exceeded the $0.70 Zacks estimate and improved sharply from a $0.49 loss a year earlier. The slight miss likely prompted some investors to lock in gains after LQDA’s substantial run-up.
• Negative Sentiment: Valuation and insider selling remain risks. Liquidia trades at a very high earnings multiple, while reported insider activity shows 116 sales versus one purchase during the past six months. Management also expects higher second-half research and development spending for the L606 Phase 3 program, which could pressure near-term margins.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on LQDA. Piper Sandler set a $129.00 price target on shares of Liquidia in a research report on Friday, July 24th. BTIG Research lifted their target price on Liquidia from $109.00 to $111.00 and gave the stock a "buy" rating in a report on Wednesday. Wall Street Zen downgraded Liquidia from a "strong-buy" rating to a "buy" rating in a report on Saturday, June 27th. Jefferies Financial Group restated a "buy" rating and set a $60.00 target price on shares of Liquidia in a research note on Monday, May 11th. Finally, Royal Bank Of Canada set a $130.00 price target on shares of Liquidia in a research note on Friday, July 24th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $98.08.

Insider Transactions at Liquidia

In other Liquidia news, insider Jason Adair sold 688 shares of the business's stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $87.53, for a total transaction of $60,220.64. Following the sale, the insider directly owned 216,438 shares in the company, valued at $18,944,818.14. This represents a 0.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Dana Boyle sold 1,600 shares of the company's stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $87.53, for a total transaction of $140,048.00. Following the sale, the chief accounting officer directly owned 167,919 shares in the company, valued at approximately $14,697,950.07. The trade was a 0.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 1,781,861 shares of company stock valued at $124,407,112 in the last three months. 25.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. TCG Crossover Management LLC purchased a new stake in shares of Liquidia in the third quarter valued at about $38,887,000. MPM Bioimpact LLC lifted its holdings in Liquidia by 600.4% in the fourth quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company's stock valued at $48,316,000 after acquiring an additional 1,200,869 shares during the period. Voloridge Investment Management LLC acquired a new position in shares of Liquidia during the 3rd quarter worth $12,571,000. Bank of New York Mellon Corp purchased a new position in shares of Liquidia in the 2nd quarter valued at about $29,694,000. Finally, Bank of America Corp DE boosted its holdings in Liquidia by 18.7% during the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company's stock worth $86,341,000 after buying an additional 360,372 shares in the last quarter. Hedge funds and other institutional investors own 64.54% of the company's stock.

Liquidia Trading Down 7.7%

The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. The stock has a market cap of $6.46 billion, a PE ratio of 522.47 and a beta of 0.58. The business's fifty day moving average is $78.22 and its 200 day moving average is $54.77.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source